ArticleJournal of endocrinological investigation2023
Phenylacetylglutamine as a novel biomarker of type 2 diabetes with distal symmetric polyneuropathy by metabolomics.
Article in Journal of endocrinological investigation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Trimethylamine N-Oxide Combined with Phenylacetylglutamine as Potential Biomarkers for Diabetic Kidney Disease.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Serum Phenylacetylglutamine Is a Potential Risk Factor for Aortic Stiffness in Patients with Chronic Hemodialysis.Diagnostics (Basel, Switzerland) · 2025Article
- Associations of fecal and blood microbiota-related metabolites with gut microbiota and type 2 diabetes in HIV infection.AIDS (London, England) · 2025Article
- Progress and perspectives of metabolic biomarkers in blood sample for diabetic microvascular complications.Metabolomics : Official journal of the Metabolomic Society · 2025Review
- Insights into the molecular underpinning of type 2 diabetes complications.Human molecular genetics · 2025Review
- Immunometabolic chaos in septic shock.Journal of leukocyte biology · 2025Article
- Blood metabolomic profile in patients with type 2 diabetes mellitus with diabetic peripheral neuropathic pain.Journal of diabetes investigation · 2025Article
- Intricate mechanism of anxiety disorder, recognizing the potential role of gut microbiota and therapeutic interventions.Metabolic brain disease · 2024Review
- Investigating the mechanism of supraspinatus tendinopathy induced by type 2 diabetes mellitus in rats using untargeted metabolomics analysis.BMC musculoskeletal disorders · 2024Article
- The Association between Gut Microbiota and Its Metabolites in Gestational Diabetes Mellitus.Journal of microbiology and biotechnology · 2024Article
- Low-Molecular-Weight Compounds Produced by the Intestinal Microbiota and Cardiovascular Disease.International journal of molecular sciences · 2024Review
- Metabolomic and lipidomic profiling of the spinal cord in type 2 diabetes mellitus rats with painful neuropathy.Metabolic brain disease · 2024Article
- Metabolic and inflammatory perturbation of diabetes associated gut dysbiosis in people living with and without HIV infection.Genome medicine · 2024Article
- Gut microbiota-dependent phenylacetylglutamine in cardiovascular disease: current knowledge and new insights.Frontiers of medicine · 2024Review
- Tryptophan metabolism and small fibre neuropathy: a correlation study.Brain communications · 2024Article
- Enhancing type 2 diabetes mellitus prediction by integrating metabolomics and tree-based boosting approaches.Frontiers in endocrinology · 2024Article
- Ultra-high performance liquid chromatography coupled to tandem mass spectrometry-based metabolomics study of diabetic distal symmetric polyneuropathy.Journal of diabetes investigation · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
purposeType 2 diabetes mellitus (T2DM) with distal symmetric polyneuropathy (DSPN) is a disease involving the nervous system caused by metabolic disorder, while the metabolic spectrum and key metabolites remain poorly defined.
methodsPlasma samples of 30 healthy controls, 30 T2DM patients, and 60 DSPN patients were subjected to nontargeted metabolomics. Potential biomarkers of DSPN were screened based on univariate and multivariate statistical analyses, ROC curve analysis, and logistic regression. Finally, another 22 patients with T2DM who developed DSPN after follow-up were selected for validation of the new biomarker based on target metabolomics.
resultsCompared with the control group and the T2DM group, 6 metabolites showed differences in the DSPN group (P < 0.05; FDR < 0.1; VIP > 1) and a rising step trend was observed. Among them, phenylacetylglutamine (PAG) and sorbitol displayed an excellent discriminatory ability and associated with disease severity. The verification results demonstrated that when T2DM progressed to DSPN, the phenylacetylglutamine content increased significantly (P = 0.004).
conclusionThe discovered and verified endogenous metabolite PAG may be a novel potential biomarker of DSPN and involved in the disease pathogenesis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.